Biomica Ltd., a clinical-stage biopharmaceutical company, has announced promising interim results from pre-clinical studies in its Irritable Bowel Syndrome (IBS) program. The findings demonstrate the effectiveness of Biomica's live bacterial consortia, BMC426 and BMC427, in alleviating symptoms commonly associated with IBS, such as abdominal pain and abnormal bowel movements. These positive outcomes provide a solid foundation for the further development of Biomica's IBS therapeutics.
IBS is a chronic disorder of the digestive system that affects approximately 4.1% of the global population. Individuals suffering from IBS often experience distressing symptoms including abdominal pain, bloating, and irregular bowel movements, which can significantly impact their quality of life. Currently available standard therapies for IBS are limited in their ability to address abdominal pain effectively. Research indicates that alterations in the gut microbiome may play a crucial role in the development of these debilitating symptoms.
The design of BMC426 and BMC427